We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy.
- Authors
Prósper, F; Solá, C; Hornedo, J; Arbona, C; Menéndez, P; Orfao, A; Lluch, A; Cortés-Funes, H; López, J J; García-Conde, J
- Abstract
The objective of our study was to determine the effect of adding r-metHuSCF to Filgrastim and cyclophosphamide for mobilization of peripheral blood progenitor cells (PBPC), on collection of CD34[sup +] cells and engraftment after autologous stem cell transplant. Twenty-three patients with previously treated stage II-IV breast cancer received cyclophosphamide (3 g/m²), Filgrastim 5 µg/kg daily and r-metHuSCF 20 µg/kg daily. Two PBPC collections were performed on consecutive days starting the day the WBC count was above 7.5 × 10[sup 3]/µl. Collection was performed between days +9 and +12 and the median number of CD34[sup +] cells collected was 9.9 × 10[sup 6]/kg (1.1-53.1) and 6.6 × 10[sup 6]/kg (1.4-33.8) for the first and second apheresis, respectively. Despite being previously treated patients, the target CD34[sup +] cell dose required for SCT was obtained in all patients. SCT was associated with rapid neutrophil and platelet engraftment and a highly significant correlation was observed between the number of CD34[sup +] cells infused and engraftment. Treatment with SCF plus filgrastim was well tolerated, with mild to moderate local skin rash being the most frequently reported adverse event. In conclusion, addition of r-metHuSCF induces mobilization of a large number of CD34[sup +] cells which results in shortening of time to engraftment and hospitalization.
- Subjects
FILGRASTIM; STEM cell transplantation
- Publication
Leukemia (08876924), 2003, Vol 17, Issue 2, p437
- ISSN
0887-6924
- Publication type
Article